Luca Issi
Stock Analyst at RBC Capital
(0.88)
# 3,524
Out of 4,792 analysts
196
Total ratings
22.95%
Success rate
-22.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Outperform | $24 → $20 | $2.64 | +657.58% | 5 | Mar 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $310 → $330 | $262.16 | +25.88% | 27 | Mar 21, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $105 → $95 | $14.75 | +544.07% | 7 | Mar 19, 2025 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.62 | +221.39% | 6 | Mar 18, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | $17 | $7.00 | +142.86% | 1 | Mar 18, 2025 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $11 → $13 | $6.13 | +112.07% | 6 | Mar 17, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.38 | +624.64% | 8 | Mar 14, 2025 | |
| VERV Verve Therapeutics | Maintains: Outperform | $17 → $15 | $3.85 | +290.12% | 7 | Mar 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $26 → $25 | $22.52 | +11.01% | 5 | Mar 3, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $39 → $35 | $2.89 | +1,113.17% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $16.46 | +57.96% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $28.52 | +145.44% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $67.48 | +3.73% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $40 | $25.73 | +55.46% | 13 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $53 → $48 | $32.66 | +46.97% | 13 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $12.06 | +248.26% | 8 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $9.75 | +146.15% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $39.21 | +45.37% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $6.67 | +349.78% | 9 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $28.10 | +138.43% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $9.42 | +377.71% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.12 | +257.14% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $80 | $4.89 | +1,535.99% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $35.13 | +119.19% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $10 | $3.94 | +153.81% | 6 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $6.64 | +125.90% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $6.89 | +683.74% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $0.79 | +1,683.44% | 5 | Aug 7, 2024 |
Lexeo Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.64
Upside: +657.58%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $262.16
Upside: +25.88%
Korro Bio
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $14.75
Upside: +544.07%
Sangamo Therapeutics
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.62
Upside: +221.39%
Ocular Therapeutix
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $7.00
Upside: +142.86%
MeiraGTx Holdings
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $6.13
Upside: +112.07%
Allogene Therapeutics
Mar 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.38
Upside: +624.64%
Verve Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.85
Upside: +290.12%
Apellis Pharmaceuticals
Mar 3, 2025
Maintains: Sector Perform
Price Target: $26 → $25
Current: $22.52
Upside: +11.01%
4D Molecular Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $2.89
Upside: +1,113.17%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $16.46
Upside: +57.96%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $28.52
Upside: +145.44%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $67.48
Upside: +3.73%
Feb 18, 2025
Reiterates: Sector Perform
Price Target: $40
Current: $25.73
Upside: +55.46%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $53 → $48
Current: $32.66
Upside: +46.97%
Feb 11, 2025
Reiterates: Outperform
Price Target: $42
Current: $12.06
Upside: +248.26%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $9.75
Upside: +146.15%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $39.21
Upside: +45.37%
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $6.67
Upside: +349.78%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $28.10
Upside: +138.43%
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $9.42
Upside: +377.71%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.12
Upside: +257.14%
Nov 15, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $4.89
Upside: +1,535.99%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $35.13
Upside: +119.19%
Nov 5, 2024
Maintains: Sector Perform
Price Target: $12 → $10
Current: $3.94
Upside: +153.81%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $6.64
Upside: +125.90%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $6.89
Upside: +683.74%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $0.79
Upside: +1,683.44%